ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling ...

Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...

More than 60 years of work by local artist Dave Nixon is exhibited in the Mari Sandoz High Plains Heritage Center.

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

The Sandoz Family Foundation, Novartis's second-largest shareholder with a 4.1% stake, has announced plans to sell a substantial portion of its holdings in the pharmaceutical giant. This strategic ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

A look ahead at exciting HS updates to be presented at AAD, including emerging therapies, new clinical insights, and procedural advancements.

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

Does the EU’s pharma patent system balance innovation and access—or block competition? Join POLITICO’s Oxford-style debate as ...

Researchers in Zurich can now verify the statics of railway bridges using a new, specially developed artificial intelligence model.